Review Article

Daedalic DNA vaccination against self antigens as a treatment for chronic kidney disease

Yuan Min Wang¹, Jimmy Jianheng Zhou¹, Ya Wang², Debbie Watson¹-³, Geoff Yu Zhang¹, Min Hu¹, Huiling Wu¹, Guoping Zheng², Yiping Wang², Anne M Durkan¹, David CH Harris², Stephen I Alexander¹

¹Centre for Kidney Research, Children’s Hospital at Westmead, Sydney, NSW, Australia; ²Centre for Transplant and Renal Research, University of Sydney at Westmead Millennium Institute, Sydney, NSW Australia; ³Centre for Medical Bioscience, University of Wollongong, NSW Australia; ⁴Collaborative Transplant Research Group, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia

Received December 10, 2012; Accepted January 17, 2013; Epub February 15, 2013; Published March 1, 2013

Abstract: Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia and worldwide. DNA vaccination has been used for targeting foreign antigens to induce immune responses and prevent autoimmune disease, viral infection and cancer. However, the use of DNA vaccination has been restricted by a limited ability to induce strong immune responses, especially against self-antigens which are limited by mechanisms of self-tolerance. Furthermore, there have been few studies on the potential of DNA vaccination in chronic inflammatory diseases, including CKD. We have established strategies of DNA vaccination targeting specific self-antigens in the immune system including co-stimulatory pathways, T cell receptors and chemokine molecules, which have been effective in protecting against the development of CKD in a variety of animal models. In particular, we find that the efficacy of DNA vaccination is improved by dendritic cell (DC) targeting and can protect against animal models of autoimmune nephritis mimicking human membranous nephropathy. In this review, we summarize several approaches that have been tested to improve the efficacy of DNA vaccination in CKD models, including enhanced DNA vaccine delivery methods, DNA vaccine modifications and new molecular targets for DNA vaccination. Finally, we discuss the specific application of DNA vaccination for preventing and treating CKD.

Keywords: DNA vaccination, dendritic cell, DEC205, CD40, cytokine, costimulatory molecular, active Heymann nephritis (HN), adriamycin nephropathy (AN)

Introduction

Chronic kidney disease (CKD) is characterized by the progressive loss of renal function and structural injury leading eventually to end stage kidney disease (ESKD) [1, 2]. Currently, treatment strategies that successfully delay progression from CKD to ESKD are limited and patients with ESKD require costly dialysis or renal transplantation. Therefore, new strategies to manage CKD are important from both a clinical and public health perspective. DNA vaccination delivers plasmid DNA encoding the target gene to induce both humoral and cellular immune responses. This strategy has been used for more than two decades to treat autoimmune disease, viral infection and cancer [3-7]. While DNA vaccines have reached clinical use, in general they have been limited by their restricted ability to induce strong immune responses [8] and this is a particular problem in generating responses to self-antigens where there is intrinsic self-tolerance [3, 9]. In addition, the potential of DNA vaccination as a therapeutic approach for CKD has not been assessed fully. Our previous studies have shown that DNA vaccination targeting T cell receptor (TCR) subsets in Heymann nephritis (HN) [10], or targeting the chemokine CCL2 (monocyte chemoattractant protein 1) in Adriamycin nephropathy (AN) are protective and induce specific cellular and antibody responses against the target antigen [11, 12]. A number of strategies have been utilized to enhance efficacy. We have recently tested a plasmid containing the gene encoding a single-chain Fv antibody specific for the dendritic cell-restricted antigen-uptake receptor DEC205 developed by the Steinman laboratory.
By cloning a gene of interest, co-stimulatory molecule CD40, into this plasmid, we have demonstrated that this particular vaccine (DEC205-CD40) can prevent the development of HN, a rat model of human membranous nephropathy (KI 2012). More broadly DC targeted vaccines against other chemokine targets such as CX3CR1 induce functional antibody responses against self-antigens [13].

We have called this induction of immune responses against targeted self antigens “daedalic in reference to the Greek myth of Daedalus who induced self-injury while flying to close to the sun.

Similar to standard vaccines, DNA vaccines are believed to confer protection through neutralizing antibodies. Our previous studies suggest that DNA vaccination results in antigen-specific antibody responses that can be measured by enzyme-linked immunosorbent assays, as well as assays that measure functional antibody activity. We have found that enhanced antigen specific T cell responses using the the tetanus toxoid element p30 in our plasmid enhances antigen specific T cell responses as measured by ELISPOT and provide additional T cell help for antibody production [12].

**Improvement of efficacy of DNA vaccine by modification of vaccine and delivery methods**

There are several ways of delivering a plasmid DNA into target cells. One of the most commonly used delivery methods is intramuscular injection. However, intramuscular injection is often not enough to elicit a strong immune response in rodents. Various approaches have therefore been adopted to improve the immunogenicity of DNA vaccines such as the prime-boost immunization of protein antigen in adjuvant and the use of modified DNA delivery systems including electroporation [14-16]. Our previous studies have shown that the administration of antigens (recombinant proteins or peptides) in Complete Freund’s Adjuvant (CFA) after injection of plasmid DNA encoding the target antigen enhance the immunogenicity of the vaccine in mice. CFA is composed of dried or inactivated mycobacterial components and itself is an immunopotentiator of cell-mediated immunity and production of antibodies by stimulating TNF-α production by APCs [17]. We have also demonstrated that fusion of the gene encoding the tetanus toxoid T helper epitope P30 with target genes is able to increase the immunogenicity of DNA vaccines by engaging T cell help [12].

Electroporation is another useful delivery approach which enhances the efficacy of DNA vaccines by facilitating plasmid entry into target cells [18]. Delivery of short pulses to the injection site causes temporary permeabilization of the cell membrane, thereby facilitating DNA uptake. An increased antigen expression in mice, guinea pigs and rabbits has been observed previously with the use of electroporation [18, 19]. Studies have suggested that applying an electric field to tissues in vivo significantly increase DNA uptake and gene expression [7, 18]. We and others have also found that electroporation substantially increases DNA delivery and DNA vaccine potency in animal models of CKD.

**Enhancement of DNA vaccination by targeting the encoded protein to dendritic cells (DCs)**

One of the most promising methods for enhancing the efficacy of DNA vaccination is the selective targeting of DNA vaccine encoded antigens to the immune cells, especially antigen presenting cells (APCs). This is due to the requirement for MHC Class I and II expression [20] and the expression of co-stimulatory molecules, particularly CD80 and CD86 which are important for the efficient antigen processing, presentation and induction of T cell immune responses. DCs have been identified as the most potent APCs that can prime T cells in vivo [21]. DC targeting can be achieved by the use of DEC205 ScFv antibody constructs in the plasmid. These encode a fusion protein comprised of the vaccine antigen and a single-chain Fv antibody (scFv) specific for the DC-restricted antigen-uptake receptor DEC205. DEC205 targeted DNA vaccines substantially increase antibody production and cellular responses [20, 22]. As showed in Figure 1, antigen encoding sequence is incorporated into a DC-targeted DNA plasmid which contains scFv sequence encoding for an antibody directed at DEC205, then the plasmid DNA is delivered intramuscularly with electroporation and taken up by DCs. DCs migrate into lymph nodes where they differentiate and induce T cell and B cell responses. Finally, antibody production and cellular response is induced by DC-targeted DNA vaccination.
DNA vaccination for treatment of CKD

DCs generate specific adaptive immunity against the vaccinated antigens or antigenic epitopes by augmenting T-cell mediated responses. After uptake of antigens, DCs migrate to secondary lymphoid organs where they process and present the antigens to naive T cells via MHC-I or II molecules inducing activation of antigen-specific T cells [23]. Antigen-specific T cells include CD4+ T cells and CD8+ T cells. CD4+ T cell subsets including the newly described T follicular helper cells secrete cytokines including IL-4 and IL-21 that induces B cell differentiation and lead to the production of protective neutralizing antibodies and formation of plasma and memory B cells [24]. Both CD4+ and CD8+ T cells can undergo further differentiation and become memory cells [25].

There has been a relatively simplistic model of Th1 and Th2 differentiation driving different immune responses generated by DNA vaccines [26]. It has been postulated that, IL-12 or IL-4

Figure 1. Immunological mechanisms of DNA vaccination in preventing Heymann Nephritis. Antigen encoding sequence is incorporated into a DC-targeted DNA plasmid which contains a scFv sequence encoding for antibodies directed against DEC205. Plasmid DNAs are delivered intramuscularly with electroporation and taken up by DCs. DCs migrate into lymph nodes where they differentiate and induce T cell and B cell responses. B cells differentiate into plasma cells and produce antigen-specific neutralizing antibodies limiting immune activation in chronic kidney disease.
DNA vaccination for treatment of CKD

can drive Th1 or Th2 cell development respectively [27, 28]. Th2 responses further activate B cells to become antibody-secreting plasma cells leading to humoral responses [29] and that the type of T helper response induced is related to the method of DNA vaccine delivery, target sites and nature of immunogens. For example, needle injection (IM or ID) can induce a Th1 response while the gene gun method induces Th2 responses [30, 31]. Our results are different from this and we have found increased immunogenicity and antibody levels associated with IFN-γ secretion and Th1 formation with the addition of adjuvants such as P30. This may reflect the need for some form of inflammation to break self-tolerance [11-13].

In standard DNA vaccination against pathogens an important advantage of DNA vaccination is its capability of raising CTL (CD8+ effector cytotoxic T-lymphocyte) responses. CTL responses are activated by differentiated DCs through the MHC-I priming pathway and further augmented by CD4+ T helper cells [29]. DNA vaccines that target the MHC-I restricted pathway via direct or cross priming of antigens greatly enhanced CTL responses in animal models [32, 33]. This was further emphasized recently with the development of a DNA vaccine encoding antigen peptide combined with a retention signal which targeted intercellular trafficking of MHC-I molecule presentation and produced significant CTL responses in mice with marked production of IFN-γ [34]. Furthermore, several studies had revealed that DNA vaccines against infectious agents such as HBV, influenza, and HIV strongly promote the CD8+ responses [23, 35, 36]. This differs from our studies against self antigens where the major aim is to induce blocking antibody responses.

Augmentation of immunity by DC-targeting DNA vaccination strategy has been tested in a number of disease models. It was previously shown that both a protective CD4+ T helper response and a CD8+ functional response were generated after vaccination of a recombinant gag virus vaccine against HIV in a mouse model with DC-targeting [37, 38]. More recent studies focused on the utilization of specific viral vectors to suppress cancers and preventing the development of HIV in mouse models. Animals that received DC-targeted vaccine composed of modified adenviral vectors generated significantly more CD8+ cells (including CD62L/CD127+ effector memory cells), produced higher levels of IL-2 and were protected from melanoma tumor growth [39]. In another study, DNA vaccination using DC-targeted recombinant Newcastle disease virus (rNDV) vectors induced significant interferon production and generated HIV-gag antigen specific humoral and CD4+/CD8+ T cell responses in mice [40]. Finally, prime studies have demonstrated a 10-fold increase of immunogenicity in rhesus macaques after immunization with DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells [41].

Autoimmune kidney disease targeted by DNA vaccination

Chronic kidney disease in humans and in mouse models involves both the cognate and innate immune systems and can be targeted at the levels of activation, differentiation and trafficking. We have shown that blockade of CD40L improves renal outcomes in models of progressive kidney disease [10, 54]. Strategies targeting either specific effector cells or the mode by which they are recruited to sites of inflammation may allow highly specific interventions that are long lasting, robust and do not have significant side effects.

Because of the clinical problems with CD40L as a clinical target due to thrombosis induced through CD40L on platelets we have focused on its ligand CD40. Many of the co-stimulatory pathways contain key molecules for therapeutic intervention including some such as belatacept which blocks CD28 activation, which have reached clinical use. CD40 is expressed by B cells as well as other APCs and its ligand CD154 which is expressed widely on T cells is a critical co-stimulatory pathway for T cell activation and the differentiation as well as class switching of B cells [42]. Blockade of CD40-CD154 is protective in a number of renal disease models such as rodent membranous glomerulonephritis, chronic proteinuric renal disease and Adriamycin nephropathy (AN) [43-45]. Recent studies have demonstrated that CD40 and CD154 neutralizing antibodies are highly effective in blocking this pathway by generating antigen specific Tregs and limiting antigen specific CD8 expansion [46], and their use has reached the stage of preclinical testing. Recent work by Steinman and others has shown the benefits of
targeting DNA encoded immunogens to DCs in situ using scFv antibodies directed at DEC205 on the DC surface [22]. We have utilized this approach in targeting CD40 to DCs. The incorporation of a DC targeting element into a DNA vaccine allows the selective expression/uptake of vaccine encoded antigen by DC, which is critical for increased efficacy of MHC class II antigen presentation inducing an immune response to CD40 generating blocking antibodies that protect against membranous glomerulonephritis.

**Chemokine and chemokine receptors: CCL2, CX3CR1**

Recently there has been an increased interest and progress in research on DNA vaccination targeting small immune biomolecules including T cell receptors CRs, cytokines and chemokines in chronic inflammatory diseases. Chemokines (chemotactic cytokine) are a family of small molecules that play an important role in inducing chemotaxis and coordinating leukocyte trafficking during an inflammatory response [47]. Fractalkine (CX3CL1), CCL2 (Monocyte chemoattractant protein 1, MCP-1) and their receptors CX3CR1 and CCR2 are two important chemokine/receptor pairs which have been identified as contributing significantly to monocyte recruitment. Their involvement in clinical diseases such as atherosclerosis, nephropathy, rheumatoid arthritis, allograft rejection and various types of cancer is widely evident [48-53]. Previous studies from our laboratories and collaborators have demonstrated that DNA vaccination against TCR subsets in Heymann nephritis, and against the chemokine CCL2 in Adriamycin nephropathy is protective and induce specific cellular and antibody responses against the target antigen [10-12]. We have recently demonstrated that a DC-targeted DNA vaccine against CX3CR1 and CCL2 successfully induces humoral and cellular responses in mice. In this model, the generated autoantibodies restrict the motility of macrophages towards activated endothelial cells shown by in vitro functional analysis [13]. These findings suggest a potential therapeutic role of chemokine/receptor DNA vaccination in preventing inflammatory diseases. Studies of DNA vaccination for CKD models are summarized in Table 1.

**Therapeutic applications for human renal diseases**

Clinical application of DNA vaccines has occurred in viral infection, cancer and autoimmune diseases in recent years. The success of DNA vaccines against multiple strains of influenza, human papillomavirus and HIV-1 in both preclinical models and clinical trials is promising [8]. However, potency and safety of DNA vaccines remain the major challenges to their application and had the major limitations in clinical applications. The ability to deliver vaccines better though gene guns and direct them to DCs allows more specific therapy without the need to increase adjuvants are major advancements. While potency is a requirement for human studies, there are also concerns regarding the use of adjuvants in chronic inflammatory conditions and of inducing potentially lifelong blockade of specific pathways in the immune system. However the results in animal studies are

**Table 1. DNA vaccination studies in kidney disease**

<table>
<thead>
<tr>
<th>Vaccine Target</th>
<th>Vaccine delivery method</th>
<th>Modification</th>
<th>Disease Model</th>
<th>Immunogenicity</th>
<th>Prevention of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCRs bupivacaine pretreatment intramuscular injection challenged with Fx1A</td>
<td>Heymann nephritis (HN) in rats</td>
<td>production of autoantibody</td>
<td>reduced proteinuria, reduced macrophage, T cells infiltration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCL2 bupivacaine pretreatment intramuscular injection</td>
<td>Adriamycin Nephropathy (AN) in rats</td>
<td>production of Anti-CCL2 Ab increased IFN-γ producing T cells</td>
<td>protected renal function, reduced glomerular and interstitial macrophage Infiltration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD40 bupivacaine pretreatment intramuscular injection electroporation challenged with Fx1A</td>
<td>Adriamycin Nephropathy (AN) in rats</td>
<td>production of anti-CD40</td>
<td>protected renal functions reduced renal structural injury</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
encouraging that specifically targeting self antigens through DNA vaccination (Daedelic vaccination) can be made potent enough to deliver clinical benefits. What remains to be tested is whether these benefits can be extended to human.

Conclusions

The new approaches described to improve DNA vaccination induce more potent cellular and humoral response and present a potential preventative and therapeutic strategy for a variety of autoimmune diseases. Co-stimulatory molecules and chemokines are important therapeutic targets for DNA vaccination to treat CKD. Modulation of DNA vaccination with adjuvant and DC targeting improves efficacy without increasing toxicity during the treatment for CKD. Further studies are required to explore combining DNA vaccination approaches with enhanced methods for delivery, modified adjuvants and new molecular gene targets. The induction of self-immune responses to block key pathways reflects many natural mechanisms of self-regulation and may offer potent therapeutic strategies for the treatment of CKD.

Address correspondence to: Yuan Min Wang, Centre for Kidney Research, Children’s Hospital at Westmead, NSW 2145, Sydney, Australia. Phone: (61-2) 98453106; Fax: 98453178; E-mail: yuan.wang@health.nsw.gov.au

References

DNA vaccination for treatment of CKD


[42] Diehl L, Den Boer AT, van der Voort EL, Melief CJ, Offringa R and Toes RE. The role of CD40 in
DNA vaccination for treatment of CKD


